Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
Cynthia Magro, J Justin Mulvey, David Berlin, Gerard Nuovo, Steven Salvatore, Joanna Harp, Amelia Baxter-Stoltzfus, Jeffrey Laurence, Cynthia Magro, J Justin Mulvey, David Berlin, Gerard Nuovo, Steven Salvatore, Joanna Harp, Amelia Baxter-Stoltzfus, Jeffrey Laurence
Abstract
Acute respiratory failure and a systemic coagulopathy are critical aspects of the morbidity and mortality characterizing infection with severe acute respiratory distress syndrome-associated coronavirus-2, the etiologic agent of Coronavirus disease 2019 (COVID-19). We examined skin and lung tissues from 5 patients with severe COVID-19 characterized by respiratory failure (n= 5) and purpuric skin rash (n = 3). COVID-19 pneumonitis was predominantly a pauci-inflammatory septal capillary injury with significant septal capillary mural and luminal fibrin deposition and permeation of the interalveolar septa by neutrophils. No viral cytopathic changes were observed and the diffuse alveolar damage (DAD) with hyaline membranes, inflammation, and type II pneumocyte hyperplasia, hallmarks of classic acute respiratory distress syndrome, were not prominent. These pulmonary findings were accompanied by significant deposits of terminal complement components C5b-9 (membrane attack complex), C4d, and mannose binding lectin (MBL)-associated serine protease (MASP)2, in the microvasculature, consistent with sustained, systemic activation of the complement pathways. The purpuric skin lesions similarly showed a pauci-inflammatory thrombogenic vasculopathy, with deposition of C5b-9 and C4d in both grossly involved and normally-appearing skin. In addition, there was co-localization of COVID-19 spike glycoproteins with C4d and C5b-9 in the interalveolar septa and the cutaneous microvasculature of 2 cases examined. In conclusion, at least a subset of sustained, severe COVID-19 may define a type of catastrophic microvascular injury syndrome mediated by activation of complement pathways and an associated procoagulant state. It provides a foundation for further exploration of the pathophysiologic importance of complement in COVID-19, and could suggest targets for specific intervention.
Copyright © 2020 Elsevier Inc. All rights reserved.
Figures
References
- Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China. 2019. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001017.
- Cucinotta D., Vanelli M. WHO declares COVID-19 a Pandemic. Acta Biomed. 2020 doi: 10.23750/abm.v91i1.93973.
- Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 doi: 10.1001/jama.2020.1585.
- Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 doi: 10.1111/jth.14768.
- Phan T. Novel coronavirus: from discovery to clinical diagnostics. Infect Genet Evol. 2020;79 doi: 10.1016/j.meegid.2020.104211.
- Gralinski L.E., Sheahan T.P., Morrison T.E. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9:e01753–18.
- Xu Z., Shi L., Wang Y. Pathologic findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 2020;8:420–422.
- Zhang H., Zhou P., Wei Y. Histopathologic changes and SARS-Cov-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020 doi: 10.7326/M20-0533.
- Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
- Gattinoni L., Coppola S., Cressoni M., Busana M., Chiumello D. Covid-19 does not lead to a “Typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 doi: 10.1164/rccm.202003-0817LE.
- Magro C.M., Poe J.C., Kim C. Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol. 2011;135:599–610.
- Magro C.M., Momtahen S., Mulvey J.J., Yassin A.H., Kaplan R.B., Laurence J.C. The role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol. 2015;37:349–359.
- Magro C.M., Pope Harman A., Klinger D. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant. 2003;3:1143–1154.
- Magro C.M., Deng A., Pope-Harman A. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation. 2002;74:1273–1280.
- Yao X.H., Li T.Y., He Z.C. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li xue za zhi = Chinese J Pathol. 2020 doi: 10.3760/cma.j.cn112151-20200312-00193.
- Chaturvedi S., Braunstein E.M., Yuan X. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020 doi: 10.1182/blood.2019003863.
- Magro C.M., Poe J.C., Kim C. Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol. 2011 doi: 10.1309/AJCP66QIMFARLZKI.
- Ruffatti A., Calligaro A., Lacognata C.S. Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. Clin Rheumatol. 2019 doi: 10.1007/s10067-019-04888-5.
- Manrique-Caballero C.L., Peerapornratana S., Formeck C., Del Rio-Pertuz G., Gomez Danies H., Kellum J.A. Typical and atypical hemolytic uremic syndrome in the critically Ill. Crit Care Clin. 2020 doi: 10.1016/j.ccc.2019.11.004.
- Fremeaux-Bacchi V., Fakhouri F., Garnier A. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554–562.
- Magro C.M., Wang X., Garrett-Bakelman F., Laurence J., Shapiro L.S., Desancho M.T. The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis. 2013 doi: 10.1186/1750-1172-8-185.
- Perera T.B., Murphy-Lavoie H.M. StatPearls Publishing; 2020. Purpura fulminans. Available at: Accessed March 28, 2020.
- Rits K., Doumas M., Mastellos D. Anovel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–4802.
- Yen Y.-T., Liao F., Hsiao C.-H., Kao C.-L., Chen Y.-C., Wu-Hsieh B.A. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80:2684–2693.
- Fan B.E., Chong V.C.L., Chan S.S.W. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020 doi: 10.1002/ajh.25774.
- Bhatraju P.K., Ghassemieh B.J., Nichols M. Covid-19 in critically ill patients in the Seattle region–case series. N Engl J Med. 2020 doi: 10.1056/NEJMoa2004500.
- Wysong A., Venkatesan P. An approach to the patient with retiform purpura. Dermatologic Ther. 2011;24:151–172.
- Laurence J., Haller H., Mannucci P.M., Nangaku M., Praga M., de Cordoba SR. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(11S1):1–15.
- Prufer F., Scheiring J., Sautter S. Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome. Sem Thromb Hemost. 2006;32:121–127.
- Noris M., Galbusera M., Gastoldi S. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715–1726.
- Zhou Y., Lu K., Pfefferle S. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol. 2010;84:8753–8764.
- Beltrame M.H., Catarino S.J., Goeldner I. The lectin pathway of complement and rheumatic heart disease. Front Ped. 2015;2:1–14.
- Krarup A., Wallis R., Presanis J.S., Gal P., Sim R.B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One. 2007;7:e623.
- Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 doi: 10.1016/j.cell.2020.02.058.
- Dodo J., Kocsis A., Gal P. Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases. Front Immunol. 2018;9:1–22.
- Srivastava P., Badhwar S., Chandran D.S., Jaryal A.K., Jyotsna V.P., Deepak K.K. Imbalance between Angiotensin II - Angiotensin (1-7) system is associated with vascular endothelial dysfunction and inflammation in type 2 diabetes with newly diagnosed hypertension. Diabetes Metab Syndr. 2019;13:2061–2068.
- Shagdarsuren E., Wellner M., Braesen J.H. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716–724.
- Rambaldi A., Khaled S., Smith M. Eur Hematol Assoc; Stockholm, Sweden: 2018. Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) June 14–17Abst PF724.
Source: PubMed